281,309 Shares in Solventum Co. (NYSE:SOLV) Acquired by Raymond James Financial Inc.

Raymond James Financial Inc. bought a new position in Solventum Co. (NYSE:SOLVFree Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 281,309 shares of the company’s stock, valued at approximately $18,583,000. Raymond James Financial Inc. owned about 0.16% of Solventum as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. Modus Advisors LLC bought a new stake in shares of Solventum during the 4th quarter worth $25,000. Stonebridge Financial Group LLC bought a new position in Solventum during the fourth quarter worth about $26,000. Crews Bank & Trust acquired a new position in Solventum during the fourth quarter worth $32,000. True Wealth Design LLC increased its holdings in shares of Solventum by 23,550.0% during the third quarter. True Wealth Design LLC now owns 473 shares of the company’s stock worth $33,000 after buying an additional 471 shares in the last quarter. Finally, Prospera Private Wealth LLC acquired a new stake in shares of Solventum in the third quarter valued at $35,000.

Solventum Trading Up 1.2 %

Shares of SOLV stock opened at $75.04 on Tuesday. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $85.92. The stock has a fifty day simple moving average of $74.65 and a two-hundred day simple moving average of $71.30. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The firm has a market capitalization of $12.98 billion and a PE ratio of 27.29.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on SOLV shares. The Goldman Sachs Group raised their price objective on shares of Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a research note on Monday, March 3rd. Mizuho lifted their price target on shares of Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, March 3rd. Bank of America lifted their price objective on shares of Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a research report on Wednesday, February 26th. Wells Fargo & Company raised their target price on shares of Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Friday, February 28th. Finally, Morgan Stanley increased their target price on shares of Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $79.86.

View Our Latest Stock Report on Solventum

Solventum Profile

(Free Report)

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

Featured Stories

Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Co. (NYSE:SOLVFree Report).

Institutional Ownership by Quarter for Solventum (NYSE:SOLV)

Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.